Less than 40% of individuals experienced: new or worsened tinnitus (37.14%), new or increased hyperglycemia (34.29%), new or worsened gastrointestinal distress (34.29%), new or worsened dizziness (34.29%), new or worsened hearing loss (28.57%), altered appetite (28.57%), weight loss (22.86%), weight gain (22.86%), new or worsened headaches (14.29%), infusion site reactions (11.43%), increased insulin requirements (8.57%), urinary tract infection (8.57%), and need for a new endocrinologist (5.71%). This evidence concerns the gene INS and Tinnitus.